

# Study of Pulmonary Hypertension in patients with Chronic Obstructive Pulmonary Disease

*Thesis*

*Submitted for partial fulfillment of the master degree in chest  
diseases*

***By:***

Mohamed Ibrahim Abdel Maksoud Hegazy  
M. B. B. CH

***Under the supervision of:***

Prof.: Hamdy Mohamed Zoair

Professor of chest diseases  
Faculty of medicine  
Al-Azhar University

Prof.: Adel Moawad Zaher

Professor of chest diseases  
Faculty of medicine  
Al-Azhar University

Dr.: Ismail Mohamed Abul Enein

Lecturer of chest diseases  
Faculty of medicine  
Al-Azhar University

**Faculty of Medicine  
Al-Azhar University  
2013**

# دراسة إرتفاع ضغط الشريان الرئوى فى مرضى انسداد الشعب الهوائية المزمن

رسالة

توطئة للحصول على درجة الماجستير فى الأمراض الصدرية

**مقدمة من الطبيب:**

محمد إبراهيم عبدالمقصود حجازى

بكالوريوس الطب و الجراحة

**تحت إشراف:**

**الأستاذ الدكتور / حمدى محمد زعير**

أستاذ الأمراض الصدرية

كلية الطب

جامعة الأزهر

**الأستاذ الدكتور / عادل معوض زاهر**

أستاذ الأمراض الصدرية

كلية الطب

جامعة الأزهر

**الدكتور / إسماعيل محمد أبو العينين**

مدرس الأمراض الصدرية

كلية الطب

جامعة الأزهر

كلية الطب

جامعة الأزهر

2013

# Acknowledgement

*Thanks to **Allah**, the Almighty who endowed me with the ability to carry out the work of this thesis.*

*I would like to express my great honor to be under the supervision of **Professor: Hamdy Mohamed Zoair**, professor of Chest Diseases, Faculty of medicine, Al-Azhar University and my deepest thanks are expressed for his guidance, great help and support throughout supervising this work,*

*I would like to express my gratitude and extend all my thanks to **Professor: Adel Moawad Zaher**, professor of Chest Diseases, Faculty of medicine, Al-Azhar University for his supervision, support and advice.*

*I would like to express my all my thanks to **Doctor: Ismail Mohamed Abul Enein**, lecturer Chest Diseases, Faculty of medicine, Al-Azhar University whose encouragement and devoted effort illuminated me to achieve this humble piece of work,*

*My deep thanks to **Professor: Sami Noah** Assist. Professor of Cardiology, Faculty of Medicine, Al-Azhar University to who spared no effort in performing echocardiography on all the patients included in the study regardless of all his responsibilities in the Cardiology Department.*

*Last but not least, I would like so much to extend my deep thanks to my colleagues who encouraged me all the way.*

# **Contents**

<b>Subjects</b>	<b>Page</b>
• <b>Introduction and aim of the work</b> .....	1
• <b>Review of literature:</b>	
- COPD.....	5
- Pulmonary arterial hypertension.....	40
- Pulmonary hypertension in COPD .....	73
• <b>Subjects and methods</b> .....	92
• <b>Results</b> .....	99
• <b>Discussion</b> .....	120
• <b>Summary and conclusion</b> .....	134
• <b>Recommendations</b> .....	136
• <b>References</b> .....	138
• <b>Arabic Summary</b>	

## **List of Abbreviations**

<b>ALK-1</b>	: Activin receptor-Like Kinase 1 gene.
<b>APAH</b>	: Associated Pulmonary Arterial Hypertension.
<b>ASE</b>	: American Society of Echocardiography.
<b>BLVR</b>	: Bronchoscopic Lung Volume Reduction.
<b>BMPR2</b>	: Bone Morphogenic Protein Receptor 2.
<b>CCBs</b>	: Calcium Channel Blockers.
<b>cGMP</b>	: cyclic Glucose Mono Phosphate.
<b>COPD</b>	: Chronic Obstructive Pulmonary Disease.
<b>DLCO</b>	: Diffusing Lung capacity for Carbon Monoxide.
<b>ERAs</b>	: Endothelin Receptor Antagonists.
<b>ET-1</b>	: Endothelin-1.
<b>ETA</b>	: Endothelin receptor A.
<b>ETB</b>	: Endothelin receptor B.
<b>FPAH</b>	: Familial Pulmonary Arterial Hypertension.
<b>FDA</b>	: Food and Drug Administration.
<b>FEV1</b>	: Forced Expiratory Volume in the first second.
<b>FVC</b>	: Forced Vital Capacity.
<b>GERD</b>	: Gastro-Esophageal Reflux Disease.
<b>GOLD</b>	: Global initiative for chronic Obstructive Lung Disease.
<b>5-HT</b>	: 5- Hydroxy Tryptamine (Serotonin).

<b>5-HTT</b>	: 5- Hydroxy Tryptamine Transporter.
<b>IPAH</b>	: Idiopathic Pulmonary Arterial Hypertension.
<b>K</b>	: Potassium.
<b>Kv</b>	: Voltage-dependant Potassium Channels.
<b>NIH</b>	: National Institute of Health.
<b>NIPPV</b>	: Non Invasive Positive Pressure Ventilation.
<b>NIV</b>	: Non Invasive Ventilation.
<b>NO</b>	: Nitric Oxide.
<b>NOS</b>	: Nitric Oxide Synthase.
<b>NYHA</b>	: New York Heart Association.
<b>PAH</b>	: Pulmonary Arterial Hypertension.
<b>PAP</b>	: Pulmonary Artery Pressure.
<b>PAWP</b>	: Pulmonary Arterial Wedge Pressure.
<b>PaCO<sub>2</sub></b>	: Pressure of arterial Carbon dioxide.
<b>PaO<sub>2</sub></b>	: Pressure of arterial Oxygen.
<b>PCH</b>	: Pulmonary Capillary Hemangiomas.
<b>PDE-5</b>	: 5 Phospho-Diesterase Enzymes.
<b>PGI<sub>2</sub></b>	: Prostaglandin I <sub>2</sub> (Prostacyclin).
<b>PH</b>	: Pulmonary Hypertension.
<b>Ppa</b>	: Pressure of pulmonary artery.
<b>PPH</b>	: Primary Pulmonary Hypertension.
<b>PVOD</b>	: Pulmonary Veno-Occlusive Disease.

**PVR** : Pulmonary Vascular Resistance.  
**RCTs** : Respiratory Centers.  
**RHC** : Right Heart Catheterization.  
**RV** : Right Ventricle.  
**SaO<sub>2</sub>** : Saturation of Arterial Oxygen.  
**TNF<sub>α</sub>** : Tumor Necrosis Factor Alpha.  
**Tx-A<sub>2</sub>** : Thromboxane- A<sub>2</sub>.  
**WHO** : World Health Organization.  
**YLD** : Years of Living with Disability.

## List of tables

Table No.	Title	Page
<b>Table (1)</b>	Classification of severity (stages of COPD).	6
<b>Table (2)</b>	GOLD 2007 advised stepwise therapy at each stage of COPD.	29
<b>Table (3)</b>	Risk factors and associated conditions for PAH.	44
<b>Table (4)</b>	WHO Clinical classification of PAH.	46
<b>Table (5)</b>	Frequency of symptoms of PH in percent of patients.	55
<b>Table (6)</b>	Description of PAP status in both study groups.	100
<b>Table (7)</b>	Relationship between PAP status and different variables in Moderate to severe COPD patients.	101
<b>Table (8)</b>	Relationship between PAP status and different variables in very severe COPD patients.	104
<b>Table (9)</b>	Comparison between group I and group II as regard age.	107

<b>Table (10)</b>	Comparison between group I and group II as regard Sex.	108
-------------------	--	-----

## **List of tables (Con.)**

<b>Table No.</b>	<b>Title</b>	<b>Page</b>
<b>Table (11)</b>	Comparison between group I and group II as regard Smoking duration.	109
<b>Table (12)</b>	Comparison between group I and group II as regard Smoking index.	110
<b>Table (13)</b>	Comparison between group I and group II as regard Hb%.	111
<b>Table (14)</b>	Comparison between group I and group II as regard PaCO <sub>2</sub> .	112
<b>Table (15)</b>	Comparison between group I and group II as regard PaO <sub>2</sub> .	113
<b>Table (16)</b>	Comparison between group I and group II as regard SaO <sub>2</sub> %.	114
<b>Table (17)</b>	Comparison between group I and group II as regard FVC%.	115
<b>Table (18)</b>	Comparison between group I and group II as regard FEV <sub>1</sub> %.	116
<b>Table (19)</b>	Comparison between group I and group II as regard FEV <sub>1</sub> / FVC.	117

<b>Table (20)</b>	Comparison between group I and group II as regard RV.Diameter.	118
<b>Table (21)</b>	Comparison between group I and group II as regard PAP.	119

## **List of figures**

<b>Fig. No.</b>	<b>Title</b>	<b>Page</b>
<b>Fig. (1)</b>	Spirometric tracings of normal airflow, mild and severe airflow limitation.	22
<b>Fig. (2)</b>	Echocardiography PHILPS 7500.	98
<b>Fig. (3)</b>	Echocardiography HP SONOS 2000.	98
<b>Fig. (4)</b>	Comparison of PAP status between both study groups.	100
<b>Fig. (5)</b>	Correlation between PAP and FEV1% in moderate to severe COPD patients.	102
<b>Fig. (6)</b>	Correlation between PAP and SaO2% in moderate to severe COPD patients.	102
<b>Fig. (7)</b>	Mean SaO2 in patients of the first group with different grades of PH.	103
<b>Fig. (8)</b>	Mean FEV1% in patients of the first group with different grades of PH.	103
<b>Fig. (9)</b>	Correlation between PAP and FEV1% in very severe COPD patients.	105
<b>Fig. (10)</b>	Correlation between PAP and SaO2% in very severe COPD patients.	105
<b>Fig. (11)</b>	Mean SaO2 in patients of the second group with different grades of PH.	106

<b>Fig. (12)</b>	Mean FEV1% in patients of the second group with different grades of PH.	106
<b>Fig. (13)</b>	Comparison between both study groups as regard age.	107

## **List of figures (Con.)**

<b>Fig. No.</b>	<b>Title</b>	<b>Page</b>
<b>Fig. (14)</b>	Comparison between both study groups as regard Sex.	108
<b>Fig. (15)</b>	Comparison between both study groups as regard Smoking duration.	109
<b>Fig. (16)</b>	Comparison between both study groups as regard Smoking index.	110
<b>Fig. (17)</b>	Comparison between both study groups as regard Hb%.	111
<b>Fig. (18)</b>	Comparison between both study groups as regard PaCO <sub>2</sub> .	112
<b>Fig. (19)</b>	Comparison between both study groups as regard PaO <sub>2</sub> .	113
<b>Fig. (20)</b>	Comparison between both study groups as regard SaO <sub>2</sub> %.	114
<b>Fig. (21)</b>	Comparison between both study groups as regard FVC%.	115
<b>Fig. (22)</b>	Comparison between both study groups as regard FEV1%.	116
<b>Fig. (23)</b>	Comparison between both study groups as	117

	regard FEV1/FVC.	
<b>Fig. (24)</b>	Comparison between both study groups as regard RV.Diameter.	118
<b>Fig. (25)</b>	Comparison between both study groups as regard PAP.	119



## Introduction

Chronic obstructive pulmonary disease is a major health problem worldwide with increasing prevalence, morbidity, and mortality (**Nikos M. Siafakas, 2007**).

COPD is one of the leading causes of disability and death in both the developed and the developing world (**D. M. Mannino, 2007**).

According to the latest WHO estimates 2007, currently 210 million people have COPD and 3 millions died of it in 2005, and by 2030, COPD will become the 4<sup>th</sup> leading cause of death worldwide (**World Health Organization, 2007**).

COPD is defined as a disease state characterized by airflow limitation that is not fully reversible. The air flow obstruction is usually both progressive and associated with abnormal inflammatory response of the lung to noxious particles or gases. Cigarette smoke can induce inflammation and directly damage the lungs. It is believed that this inflammation can then lead to COPD (**Pauwels et al., 2001**).

The symptoms of COPD range from chronic cough, sputum production and wheezing to more severe symptoms, such as dyspnea, poor exercise tolerance, and signs or symptoms of right sided heart failure (**National Heart, Lung and Blood Institute, 2007**).

Pulmonary hypertension (PH) is the major cardiovascular complication of COPD and is associated with the development of cor pulmonale and a poor prognosis (**Mac Nee, 1994**).



Approximately 1% of COPD patient will develop severe PH " a mean PAP > 40 mmHg", while 5% will develop moderate PH " mean PAP > 35" **(Thabut et al., 2005).**

When severe PH is diagnosed in patients with COPD, another cause of this abnormality is often present. Therefore, patients with COPD and a pulmonary mean artery pressure (Ppa) of more than 35-40mmHg or systolic pulmonary artery pressure of more than 50-55mmHg should undergo a thorough workup to look for other causes of PH **(Sajkov et al., 1999).**

Recent data suggest that there is a subgroup of patients 1 to 3% who show severe PH out of the proportion to the degree of airway impairment **(Thabut et al., 2005).**

In COPD, pulmonary vessels can undergo profound fibrocellular changes that lead to pulmonary vascular remodeling. The remodeling process is intimately related to the endothelial function. Impairment of endothelial function has been demonstrated in pulmonary arteries of patients with mild COPD **(Peinado et al., 1998).**

Considering that the endothelium plays a fundamental role in regulating the vascular tone and modulating cellular proliferation in the vessel wall, it is conceivable that changes at the endothelial level might be at the origin of the development of PH in COPD **(Dinh-Xuan et al., 1991).**



## Aim of the work

The aim of the work is to study the effect of chronic obstructive pulmonary disease on pulmonary artery pressure and to identify the relation between hypoxemia and FEV1% on one hand and the degree of pulmonary hypertension on the other hand.